Annapurna Therapeutics Limited

Annapurna Therapeutics is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. Annapurna’s product pipeline includes programs for alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), the cardiomyopathy associated with Friedreich’s ataxia and severe allergy. Annapurna Therapeutics was acquired by Avalanche Biotechnologies, Inc. in 2016.

Fesarius Therapeutics, Inc.

Fesarius Therapeutics is developing engineered tissue scaffold products for the skin and dermal layers. The products are based off the patent-pending microstructure-containing gel scaffold technology developed at Cornell. The acellular skin replacement will aim to benefit those with wounds resulting from burns, plastic surgery, tumor removal, and other forms of trauma. The company joined the National Institutes of Health as part of its I-Corps @ NIH Winter 2020 Program in February 2020.

CycloPure, Inc.

CycloPure is engaged in the design, development, and commercialization of a new class of highly adsorbent materials for use in the separation and removal of pollutants, VOCs, and other organic compounds from water and air. The technology was partly developed by the Helbling Research Group at The School of Civil and Environmental Engineering. CycloPure has raised $8.81M in funding to date.

Lumendi AG

Lumendi Ltd., is focused on the development of new minimal invasive surgical tools and devices that will provide solutions for minimally invasive gastrointestinal surgeries. The company’s first product is an add-on to any commercially available endoscope that will avoid invasive colon resections to treat more complex gastrointestinal diseases.

Angiocrine Bioscience, Inc.

Angiocrine Bioscience, Inc., is developing both research and therapeutic products using stem and endothelial cell related technologies.

WOTN, LLC

WOTN is a risk software company that provides an independent, real-time, simulation-based risk management platform for the $1T commercial mortgage backed securities market. The patent pending technology provides risk measurements on demand for loans and bonds in the derivative structure compliant with Basel in a comprehensive portfolio management system.

TaggPic, Inc.

TaggPic transforms static 2D photos into auto-tagged, geo-positioned, and intelligently connected platforms. TaggPic’s crowd-fueled computer vision technology instantly recognizes landmarks, buildings, and other objects in images without the need for GPS data or manual tagging. TaggPic was acquired by Google in 2014.

TeraPore Technologies, Inc.

TeraPore Technologies, Inc. develops membrane technologies for high-permeability, high-resolution separations including purification of biological fluids.

Immunovent, LLC

Immunovent, LLC is focused on the commercialization of next-generation technologies for allergy diagnosis. The company is developing the Local Allergy Mucosal Brush Test (LAMB-Dx), the first quantitative allergy diagnostic that will enable physicians to accurately test for both airborne and food allergies precisely where the clinical symptoms are occurring – in the mouth and nose.

ZYMtronix, Inc.

ZYMtronix is a biotechnology startup that services enzyme and pharmaceutical manufacturers. ZYMtronix immobilizes and optimizes biocatalysts for continuous manufacturing using green chemistry principles to lower the costs and increase the yields of drug manufacturing.